Cantor Fitzgerald Initiates Coverage On Akero Therapeutics with Overweight Rating, Announces Price Target of $69
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal has initiated coverage on Akero Therapeutics (NASDAQ:AKRO) with an Overweight rating and a price target of $69.
September 19, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akero Therapeutics has been given an Overweight rating by Cantor Fitzgerald, with a price target of $69.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Akero Therapeutics. The price target of $69 suggests significant upside potential from the current levels. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100